Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2018 1
2019 3
2020 4
2021 4
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Grade 1 Colitis, CTCAE"
Page 1
Clinical Characteristics and Outcomes of Gastritis Associated With Immune Checkpoint Inhibitors: Scoping Review.
Obeidat A, Silangcruz K, Kozai L, Wien E, Fujiwara Y, Nishimura Y. Obeidat A, et al. J Immunother. 2022 Oct 1;45(8):363-369. doi: 10.1097/CJI.0000000000000435. Epub 2022 Aug 16. J Immunother. 2022. PMID: 35972801 Review.
Nivolumab, pembrolizumab, and combination therapy with those and cytotoxic T-lymphocyte-associated antigen-4 inhibitor (ipilimumab) were commonly used in those with IMG. 59.8% had epigastric pain, and 50% had erosive gastritis. 87.5% had Common Terminology Criteria for Adverse Ev …
Nivolumab, pembrolizumab, and combination therapy with those and cytotoxic T-lymphocyte-associated antigen-4 inhibitor (ipilimumab) were com …
COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis.
Holmstroem RB, Nielsen OH, Jacobsen S, Riis LB, Theile S, Bjerrum JT, Vilmann P, Johansen JS, Boisen MK, Eefsen RHL, Marie Svane I, Nielsen DL, Chen IM. Holmstroem RB, et al. J Immunother Cancer. 2022 Sep;10(9):e005111. doi: 10.1136/jitc-2022-005111. J Immunother Cancer. 2022. PMID: 36096534 Free PMC article. Clinical Trial.
We examined whether interleukin-6 blockade by tocilizumab reduced ICI-induced colitis and arthritis. PATIENTS AND METHODS: Patients with solid cancer experiencing Common Terminology Criteria for Adverse Events (CTCAE v5.0) grade >1 ICI-induced co …
We examined whether interleukin-6 blockade by tocilizumab reduced ICI-induced colitis and arthritis. PATIENTS AND METHODS: Patients w …
Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?
Cheung VTF, Gupta T, Olsson-Brown A, Subramanian S, Sasson SC, Heseltine J, Fryer E, Collantes E, Sacco JJ, Pirmohamed M, Simmons A, Klenerman P, Tuthill M, Protheroe AS, Chitnis M, Fairfax BP, Payne MJ, Middleton MR, Brain O. Cheung VTF, et al. Br J Cancer. 2020 Jul;123(2):207-215. doi: 10.1038/s41416-020-0882-y. Epub 2020 May 18. Br J Cancer. 2020. PMID: 32418993 Free PMC article.

G3/4 colitis patients are more likely to need infliximab (p < 0.0001) but colitis grade does not correlate with steroid duration. ...Our data support utilising endoscopic scoring for patients with >grade 1 CTCAE disease, and demonst

…

G3/4 colitis patients are more likely to need infliximab (p < 0.0001) but colitis grade does not correlate with ster

…
The Effect of Concurrent Stereotactic Body Radiation and Anti-PD-1 Therapy for Recurrent Metastatic Sarcoma.
Callaghan CM, Seyedin SN, Mohiuddin IH, Hawkes KL, Petronek MS, Anderson CM, Buatti JM, Milhem MM, Monga V, Allen BG. Callaghan CM, et al. Radiat Res. 2020 Aug 1;194(2):124-132. doi: 10.1667/RADE-20-00017. Radiat Res. 2020. PMID: 32845986 Free PMC article.
Acute and chronic toxicity were recorded using Common Terminology Criteria for Adverse Events (CTCAE, version 5.0). SBRT-treated tumor control was assessed using Response Evaluation Criteria in Solid Tumors (RECIST version 1.1). ...Grade 3 toxicities i …
Acute and chronic toxicity were recorded using Common Terminology Criteria for Adverse Events (CTCAE, version 5.0). SBRT-treated tumo …
Oral beclomethasone dipropionate is an effective treatment for immune checkpoint inhibitor induced colitis.
Alexander JL, Ibraheim H, Richards C, Shum B, Pavlidis P, Hunter N, Teare JP, Wotherspoon A, Furness A, Turajlic S, Pickering L, Larkin J, Speight A, Papa S, Powell N. Alexander JL, et al. J Immunother Cancer. 2022 Sep;10(9):e005490. doi: 10.1136/jitc-2022-005490. J Immunother Cancer. 2022. PMID: 36113896 Free PMC article.
RESULTS: Twenty-two patients (14 male) with a median age of 64 (range 45-84) with CPI-induced colitis were treated with BD. At baseline, the median number of loose stools in a 24-hour period was six (common terminology criteria for adverse events, CTCAE grade …
RESULTS: Twenty-two patients (14 male) with a median age of 64 (range 45-84) with CPI-induced colitis were treated with BD. At baseli …
Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study.
Heppt MV, Amaral T, Kähler KC, Heinzerling L, Hassel JC, Meissner M, Kreuzberg N, Loquai C, Reinhardt L, Utikal J, Dabrowski E, Gesierich A, Pföhler C, Terheyden P, Thoms KM, Zimmer L, Eigentler TK, Kirchberger MC, Stege HM, Meier F, Schlaak M, Berking C. Heppt MV, et al. J Immunother Cancer. 2019 Nov 13;7(1):299. doi: 10.1186/s40425-019-0800-0. J Immunother Cancer. 2019. PMID: 31722735 Free PMC article.
The median OS was estimated to 16.1 months (95% CI 12.9-19.3). Regarding safety, 39.1% of treated patients experienced a severe, treatment-related adverse event according to the CTCAE criteria (grade 3: 37.5%; grade 4: 1.6%). The most com …
The median OS was estimated to 16.1 months (95% CI 12.9-19.3). Regarding safety, 39.1% of treated patients experienced a sever …
Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab.
Alexander JL, Ibraheim H, Sheth B, Little J, Khan MS, Richards C, Hunter N, Chauhan D, Ratnakumaran R, McHugh K, Pinato DJ, Nathan P, Choy J, Crusz SM, Furness A, Turajlic S, Pickering L, Larkin J, Teare JP, Papa S, Speight A, Sharma A, Powell N. Alexander JL, et al. J Immunother Cancer. 2021 Jul;9(7):e002742. doi: 10.1136/jitc-2021-002742. J Immunother Cancer. 2021. PMID: 34233964 Free PMC article.
METHODS: We conducted a multicenter (six cancer centers), cohort study of outcomes in patients treated with IFX for corticosteroid-refractory CPI-induced enterocolitis between 2007 and 2020. The primary outcome was corticosteroid-free clinical remission (CFCR) with Common …
METHODS: We conducted a multicenter (six cancer centers), cohort study of outcomes in patients treated with IFX for corticosteroid-refractor …
A real-world data of Immune checkpoint inhibitors in solid tumors from India.
Noronha V, Abraham G, Patil V, Joshi A, Menon N, Mahajan A, Janu A, Jain S, Talreja VT, Kapoor A, Kumar Singh G, Khaddar S, Gupta K, Rathinasamy N, Srinivas S, Agrawal A, Ventrapati P, Prabhash K. Noronha V, et al. Cancer Med. 2021 Mar;10(5):1525-1534. doi: 10.1002/cam4.3617. Epub 2021 Feb 16. Cancer Med. 2021. PMID: 33591635 Free PMC article.
METHODS: This was a single center retrospective analysis of prospective data base of patients with non-melanoma solid tumors who were treated with immunotherapy from August 2015 to November 2018. Adverse events during immunotherapy were documented and graded using CTCAE …
METHODS: This was a single center retrospective analysis of prospective data base of patients with non-melanoma solid tumors who were treate …
Stereotactic body radiation therapy for the treatment of localized prostate cancer in men with underlying inflammatory bowel disease.
Lischalk JW, Blacksburg S, Mendez C, Repka M, Sanchez A, Carpenter T, Witten M, Garbus JE, Evans A, Collins SP, Katz A, Haas J. Lischalk JW, et al. Radiat Oncol. 2021 Jul 9;16(1):126. doi: 10.1186/s13014-021-01850-1. Radiat Oncol. 2021. PMID: 34243797 Free PMC article.
The majority (n = 18) were diagnosed with ulcerative colitis and were being treated with local steroid suppositories for IBD. No biochemical relapses were observed in the IBD cohort with early follow up. High-grade acute and late toxicities were rare (n = 1, …
The majority (n = 18) were diagnosed with ulcerative colitis and were being treated with local steroid suppositories for IBD. No bioc …
Safety and tolerability of stereotactic radiotherapy combined with durvalumab with or without tremelimumab in advanced non-small cell lung cancer, the phase I SICI trial.
Kievit H, Muntinghe-Wagenaar MB, Hijmering-Kappelle LBM, Hiddinga BI, Ubbels JF, Wijsman R, Slingers G, de Vries R, Groen HJM, Kerstjens HAM, van der Wekken AJ, Hiltermann TJN. Kievit H, et al. Lung Cancer. 2023 Apr;178:96-102. doi: 10.1016/j.lungcan.2023.02.004. Epub 2023 Feb 7. Lung Cancer. 2023. PMID: 36806899 Free article. Clinical Trial.
Median irradiated volume was 9.13 cc, on a median primary tumor volume of 79 cc. There were seven patients with grade 1-2, and two patients with grade 3 treatment related adverse events. There was 1 dose limiting toxicity (colitis) with double i …
Median irradiated volume was 9.13 cc, on a median primary tumor volume of 79 cc. There were seven patients with grade 1-2, and …
16 results